Skip to content
★ Sign in to follow
REYON Pharmaceutical Co., Ltd. logo

REYON Pharmaceutical Co., Ltd. Stock: price and insider trades · South Korea

이연제약

KR·Mcap ₩171.9BHealth Care

No insider purchase over the last 90 days. The latest, by 쿼드자산운용, was filed 09 Jul 2025.

REYON Pharmaceutical Co., Ltd.: what insiders have been doing

REYON Pharmaceutical Co., Ltd. is a Health Care company. Its directors and officers file their transactions with DART (FSS). Between 1 November 2025 and 1 November 2026, 1 insider published 1 filing.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

No insider has bought REYON Pharmaceutical Co., Ltd. shares on the open market in the past twelve months.

Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 1 filing, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 2 purchases and 6 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
37
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€16M
6 ops. · all time

Who traded when

BuySale
쿼드자산운용1 buy
Fundamental score
Ranked 24,876 of 26,913 companies
18.9
score / 100
Value
21
Quality
17
FCF yld-3.8%
Earn yld-17%
EV/EBITDA19.0x
ROE-16%
Gross mgn26%
Net mgn-20%
Debt/EBITDA10.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩9,370
Analyst consensus
·
Income statement
Revenue₩145.9B
Gross profit₩38.2B26% margin
EBITDA₩20.4B14% margin
Net income-₩29.6B-23.9% margin
Valuation
Beta0.48
Balance sheet & cash
Market cap₩171.9B
Total debt₩216.1B
Free Cash Flow-₩6.5B
Debt / Equity111%
Profitability & ownership
ROE-15.9%
ROA-4.1%
% insiders53.8%
% institutions0.4%
Last declaration on 12 March 2026
Declarations40 total
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • Other
    Other(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Related company / holdingExecutives
    €1.2Mest.0DART
    161,613 sharesKRXDART:20250709000456
    Canonical exit: 31 Aug 2025 (T+90)
  • ●
    Executives
    Executives
    0DART
  • ●
    Executives
    0DART
    0KRXDART:20241203000202
  • ●
    Executives
    0DART
    0KRXDART:20241104000248
  • ▼
    Related company / holdingExecutives
    €16.1Mest.0DART
    1,540,592 sharesKRXDART:20241101000353
  • 2,508,960 sharesKRXDART:20241029000243
    Canonical exit: 23 Jan 2025 (T+90)
  • ●
    Executives
    0DART
    0KRXDART:20241028000296
  • ●
    Executives
    0DART
    0KRXDART:20240906000474
  • ●
    Executives
    0DART
    0KRXDART:20240830001921
  • ●
    Executives
    0DART
    0KRXDART:20231108000403
  • ▼
    대표이사 회장Executives
    0DART
    ShareKRXDART:20231108000409
  • ●
    Executives
    0DART
    0KRXDART:20231027000427
  • ●
    Executives
    0DART
    0KRXDART:20230901000334
  • ●
    Executives
    0DART
    0KRXDART:20230726000494
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives(filed)
    0DART
    0KRXDART:20230307000662
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    대표이사 회장Executives(filed)
    0DART
    ShareKRXDART:20221202000634
  • ▼
    대표이사 회장Executives(filed)
    0DART
    ShareKRXDART:20221202000644
  • ●
    Executives(filed)
    0DART
    0KRXDART:20221202000614
  • ●
    Executives(filed)
    0DART
    0KRXDART:20220907000421

25 of 40 declarations

About REYON Pharmaceutical Co., Ltd.

이연제약 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development and manufacturing of innovative medications.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations